home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

254 rows where filing_period = "second_quarter", filing_year = 2013 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 254 ✖

filing_year 1

  • 2013 · 254 ✖

filing_period 1

  • second_quarter · 254 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
1401274 PARRY, ROMANI, DECONCINI & SYMMS 22cf9f9b-6729-4ca8-8839-7b4d2c58d19f 2T PARRY, ROMANI, DECONCINI & SYMMS 30792 BRAIDWOOD MANAGEMENT, INC. 2013 second_quarter PHA Issues related to the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. HOUSE OF REPRESENTATIVES,SENATE     0 1 2013-05-20T16:11:08.293000-04:00
1401282 PARRY, ROMANI, DECONCINI & SYMMS 62a95ebf-7a7c-45a2-83b0-2db37e871756 2T PARRY, ROMANI, DECONCINI & SYMMS 30792 DIAMONDBACK DRUGS 2013 second_quarter PHA Issues related to the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. HOUSE OF REPRESENTATIVES,SENATE     0 1 2013-05-20T16:20:10.977000-04:00
1401286 PARRY, ROMANI, DECONCINI & SYMMS 997802ff-308f-43af-8df5-bbef2d10ffc3 2T PARRY, ROMANI, DECONCINI & SYMMS 30792 VETERINARY PHARMACIES OF AMERICA, INC. 2013 second_quarter PHA Issues related to the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. HOUSE OF REPRESENTATIVES,SENATE     0 1 2013-05-20T16:34:13.347000-04:00
1401291 PARRY, ROMANI, DECONCINI & SYMMS 784014c6-1a40-482c-9cc6-cc890ab5188b 2T PARRY, ROMANI, DECONCINI & SYMMS 30792 WEDGEWOOD VILLAGE PHARMACY, INC. 2013 second_quarter PHA Issues related to the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. HOUSE OF REPRESENTATIVES,SENATE     0 1 2013-05-20T16:45:15.340000-04:00
1401307 PARRY, ROMANI, DECONCINI & SYMMS 97180f1b-de8b-4e10-9e7c-456baf7320eb 2T PARRY, ROMANI, DECONCINI & SYMMS 30792 WOMEN'S INTERNATIONAL PHARMACY, INC. 2013 second_quarter PHA Issues related to the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. HOUSE OF REPRESENTATIVES,SENATE     0 1 2013-05-20T17:05:18.880000-04:00
1401590 LONG TERM CARE PHARMACY ALLIANCE c0ca3a18-96b9-41df-87a8-1f5a68db2e01 2T LONG TERM CARE PHARMACY ALLIANCE 400309443 LONG TERM CARE PHARMACY ALLIANCE 2013 second_quarter PHA Medicare Part D Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   160000 0 1 2013-06-04T12:05:12.027000-04:00
1402249 CYBER SECURITY RESEARCH CONSULTANTS, LLC 3b3a1ce0-1ebe-490c-881f-90a20e9cd1b1 Q2 CYBER SECURITY RESEARCH CONSULTANTS, LLC 91694 PDFRAZER CONSULTING INC CANADIAN INTERNATIONAL PHARMACY ASSOCIATION 2013 second_quarter PHA Monitoring drug importation legislation SENATE 20000   0 0 2013-07-02T12:35:13.480000-04:00
1402282 INJURED WORKERS PHARMACY 1f021ac8-3c52-4bcd-b7d3-2ea08d27983b Q2 INJURED WORKERS PHARMACY 400765309 INJURED WORKERS PHARMACY 2013 second_quarter PHA Transparency of Pharmacy Benefits Managers (bill sponsored by Rep. McMorris-Rodgers and Senator Mark Pryor); Longshoreman and Harbor Workers Amendement Act of 2011sponsored by Senator Isakson. HOUSE OF REPRESENTATIVES,SENATE     0 0 2013-07-02T12:46:24.800000-04:00
1402453 AMERICAN COLLEGE OF CLINICAL PHARMACY 4670cda4-d6af-4311-b1bd-61e74dbf7a6a Q2 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2013 second_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   111725 0 0 2013-07-02T16:07:53.320000-04:00
1402742 VENABLE LLP 944879b8-a84e-4566-8432-c76beec8a774 Q2 VENABLE LLP 39941 ENDO PHARMACEUTICALS INC 2013 second_quarter PHA Issues related to tamper resistant formulation of pharmaceuticals drugs. The Life Sciences Jobs and Investment Act. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2013-07-03T16:55:17.880000-04:00
1403233 UNIVERSITY OF IOWA 8bb0490d-8531-450f-8557-c87606ae1355 Q2 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2013 second_quarter PHA Increased appropriations for systems to shorten the time between development of a drug and its release to the public FDA reform as it relates to drug development and research Collaborative research on drug development Human factors research related to neuropharmaceuticals Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT)   29312 0 0 2013-07-08T12:52:43.863000-04:00
1403320 THORSEN FRENCH ADVOCACY LLC a2fc354e-f093-4917-b6f3-3bad5a39cbf6 Q2 THORSEN FRENCH ADVOCACY LLC 400599826 ASTRAZENECA PHARMACEUTICALS LP 2013 second_quarter PHA Issues realted to access to pharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2013-07-08T16:11:38.377000-04:00
1404120 CAPITOL HILL CONSULTING GROUP fe9e11d5-6549-45ac-bebc-d004274e068a Q2 CAPITOL HILL CONSULTING GROUP 72053 PURDUE PHARMA LLP 2013 second_quarter PHA Controlled Drug Substances Act (21 USC 13) Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) HOUSE OF REPRESENTATIVES,SENATE 31500   0 0 2013-07-10T12:15:13.623000-04:00
1404137 CAPITOL HILL CONSULTING GROUP 63c4d585-7e15-427a-b065-aac04e8bd6f8 Q2 CAPITOL HILL CONSULTING GROUP 72053 PROFESSIONAL COMPOUNDING CENTERS OF AMERICA 2013 second_quarter PHA Compounding pharmacy and FDA issues Pharmaceutical Compounding Quality and Accounting Act (S. 959) HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2013-07-10T12:26:24.663000-04:00
1404491 DUTKO WORLDWIDE, LLC 0a96bb96-18c9-449b-af1d-3cdd8169e685 Q2 DUTKO WORLDWIDE, LLC 12868 NEWAYS INTERNATIONAL 2013 second_quarter PHA Monitor legislation pertaining to dietary supplements and pharmaceuticals, particularly the Food Safety Modernization Act (PL 111-353) and Patient Protection and Affordable Care Act (PL 111-148). Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2013-07-10T20:01:28.467000-04:00
1404612 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 370fe154-e056-4be4-9250-2d704f564021 Q2 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2013 second_quarter PHA Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; mandatory recall authority of the FDA; Rx-to-OTC SwitchSupporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE   290000 0 0 2013-07-11T09:56:40.260000-04:00
1404807 LNE GROUP 1a4919b1-8c69-4be0-b3f4-28eea72499a7 Q2 LNE GROUP 308811 OHIOGUIDESTONE (FORMALLY KNOWN AS GUIDESTONE) 2013 second_quarter PHA Lobbied on pharmacy issues HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2013-07-11T12:00:13.973000-04:00
1404866 UPS (UNITED PARCEL SERVICE) 78e0dd0c-419b-43de-a972-e0046438ed34 Q2 UPS (UNITED PARCEL SERVICE) 39223 UPS (UNITED PARCEL SERVICE) 2013 second_quarter PHA HR 1919 / S.959 Healthcare Supply Chain Safety related to Track & Trace legislation Air Force, Dept of,Army, Dept of (Other),Commerce, Dept of (DOC),Executive Office of the President (EOP),Federal Aviation Administration (FAA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Navy, Dept of,SENATE,State, Dept of (DOS),Transportation, Dept of (DOT),Treasury, Dept of,U.S. Trade Representative (USTR),White House Office   1201541 0 0 2013-07-11T12:28:30.807000-04:00
1404907 LNE GROUP 4b7bafcc-e48a-4c33-81dc-14a23b2acfe7 Q2 LNE GROUP 308811 INTRINSIQ MATERIALS 2013 second_quarter PHA Lobbied on pharmacy issues HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2013-07-11T12:48:43.403000-04:00
1405105 MCDERMOTT WILL & SCHULTE LLP 225dfbdc-0848-4400-b531-d1854ce61718 Q2 MCDERMOTT WILL & SCHULTE LLP 24338 ALLERGAN, INC. 2013 second_quarter PHA Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2013-07-11T14:55:05.490000-04:00
1405111 MASSACHUSETTS MEDICAL SOCIETY 0b38c9dc-2823-4137-9aa0-2e81237feec1 Q2 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2013 second_quarter PHA HR 1285, S 621 - Safe Prescribing Act of 2013, to amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug Drug Diversion issues including, reauthorization of the NASPER, appropriations for the Substance Abuse & Mental health Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE   60000 0 0 2013-07-11T14:58:10-04:00
1405295 STANTON PARK GROUP f9cb26bf-85a7-426a-8b5c-e9a8f659a7f4 Q2 STANTON PARK GROUP 83717 ALKERMES, INC. 2013 second_quarter PHA increasing acceptance of medication assisted therapy in treating abuse of alcohol and opioid dependence HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2013-07-11T16:36:35.893000-04:00
1405542 RED+BLUE STRATEGIES 12163170-b240-4e77-8268-348df7ad91c3 Q2 RED+BLUE STRATEGIES 400693064 EXPRESS SCRIPTS INC. 2013 second_quarter PHA H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negatively impact access to mail order pharmacy Rules, regulations and guidance specific to prescription drug pricing, generic utilization and specialty pharmacy.Issues impacting PBMs in up coming health related legislation. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Changes in International Naming policies for generic medications. ACA-related regulations impacting new rules for Exchanges specific to the promulgation of the prescription drug benefits. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2013-07-12T11:34:52.797000-04:00
1405560 PARRY, ROMANI, DECONCINI & SYMMS c159a860-411e-43d2-8e55-733eda0bcf96 Q2 PARRY, ROMANI, DECONCINI & SYMMS 30792 POZEN, INC. 2013 second_quarter PHA Support legislation to provide incentives for new drug development. No specific bills pending. HOUSE OF REPRESENTATIVES,SENATE 36000   0 0 2013-07-12T11:55:03.530000-04:00
1406459 CARDINAL HEALTH, INC. e15f3100-ff77-4f4e-8c67-5935208baf2e Q2 CARDINAL HEALTH, INC. 58055 CARDINAL HEALTH INC 2013 second_quarter PHA S. 621/HR 1285; "Safe Prescribing Act of 2013" (All provisions, including but not limited to Section 2, related to the Physical Security Requirements for storing hydrocodone products.) HOUSE OF REPRESENTATIVES,SENATE   360000 0 0 2013-07-15T10:05:03.967000-04:00
1406473 APOTEX CORP. fc313776-8f9a-496a-86b4-82e5734be4c9 Q2 APOTEX CORP. 310973 APOTEX CORP. 2013 second_quarter PHA S. 504, The Fair and Immediate Release of Generics Act, provisions relating to market blockages caused by parked 180 day exclusivity periods S. 214, The Preserve Access to Affordable Pharmaceuticals Act, provisions relating to the legality of "reverse payment" patent settlementsFederal Trade Commission v. Actavis Supreme Court Case No. 12-416 as this case pertains to S. 504, S. 214, and to federal policy on "reverse payment" settlements Potential legislation relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing H.R. 1919, the Safeguarding America's Pharmaceutical Act of 2013, S. 959, the Pharmaceutical Compounding Quality and Accountability Act, Title II, Drug Supply Chain Security, provisions relating to the establishment of a federal track and trace system for pharmaceuticals Federal policy relating to the adoption of an electronic labeling system for pharmaceuticals, inlcuding as proposed in HR 1919 S. 1244, Fiscal Year 2014 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations bill, Title VI, Related Agency and Food and Drug Administration, provisions relating to the sequester's impact on the generic drug user fee program Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE   140000 0 0 2013-07-15T10:22:09.377000-04:00
1406527 PD FRAZER CONSULTING, INC. 2ae53d7f-26c4-4896-902b-57932ac22536 Q2 PD FRAZER CONSULTING, INC. 65998 CANADA INTERNATIONAL PHARMACY ASSOCIATION 2013 second_quarter PHA Monitor the development of proposed bills about the importation of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2013-07-15T10:58:38.067000-04:00
1406570 WEXFORD STRATEGIC ADVISORS, INC. 8ec1a8ea-e272-4f17-838e-f73943450a26 Q2 WEXFORD STRATEGIC ADVISORS, INC. 401047947 P.D. FRAZER CONSULTING, INC., CANADIAN INTERNATIONAL PHARMACY ASSOCIATION 2013 second_quarter PHA Monitor the development of proposed bills about the importation of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2013-07-15T11:18:01.893000-04:00
1406606 ANIMAL HEALTH INSTITUTE 5c3d2983-d63b-4c99-8d7e-6862d0fb80a0 Q2 ANIMAL HEALTH INSTITUTE 4037 ANIMAL HEALTH INSTITUTE 2013 second_quarter PHA Issues related to illegal drug compounding, including S959, Pharmaceutical Compounding Quality and Accountability Act.; Veterinary Drug Enforcement Administration issues - Veterinary Medicine Mobility Act of 2013. HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)   50000 0 0 2013-07-15T11:29:16.807000-04:00
1406792 KATE MOSS e1d40fa9-de72-4280-bb4b-2bc8c78ce8e7 Q2 KATE MOSS 25988 CVS HEALTH 2013 second_quarter PHA Issues related to prescription drug abuseand drug supply chain safety HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2013-07-15T13:27:40.970000-04:00
1407051 BLUECROSS BLUESHIELD OF TENNESSEE fcf58b17-39ac-4eb4-864d-aafa2c30a273 Q2 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2013 second_quarter PHA General Pharmacy Issues HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2013-07-15T14:40:37.833000-04:00
1407070 PHILIP W. JOHNSTON ASSOCIATES 088f1f11-3a05-424e-a07f-0086be958115 Q2 PHILIP W. JOHNSTON ASSOCIATES 400278335 LUMARA HEALTH (FKA KV PHARMACEUTICAL COMPANY) 2013 second_quarter PHA Legislation regulating compounding pharmacies to improve patient safety. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2013-07-15T14:46:46.017000-04:00
1407327 ROCK & ASSOCIATES ab512380-0599-4611-bb04-5888bafbbf95 Q2 ROCK & ASSOCIATES 33545 WOMEN'S INTERNATIONAL PHARMACY 2013 second_quarter PHA S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. HOUSE OF REPRESENTATIVES,SENATE 9375   0 0 2013-07-15T16:04:39.283000-04:00
1407332 HEARTLAND SOLUTIONS GROUP, INC. 9e742772-54b7-457a-a477-ee2e85955dc9 Q2 HEARTLAND SOLUTIONS GROUP, INC. 312133 ZEBRA TECHNOLOGIES CORPORATION 2013 second_quarter PHA Any and all issues related to barcode, secure identification and real-time location systems. HOUSE OF REPRESENTATIVES,SENATE 48000   0 0 2013-07-15T16:04:41.080000-04:00
1407402 ROCK & ASSOCIATES eb9acebc-db43-492f-be6e-cbb9d4930a4a Q2 ROCK & ASSOCIATES 33545 BRAIDWOOD MANAGEMENT, INC. 2013 second_quarter PHA S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. HOUSE OF REPRESENTATIVES,SENATE 9375   0 0 2013-07-15T16:35:09.837000-04:00
1407421 ROCK & ASSOCIATES 7094df03-d02a-4234-962a-3ea487490c0f Q2 ROCK & ASSOCIATES 33545 CAPITOL HILL CONSULTING GROUP (ON BEHALF OF WELLNESS PHARMACY) 2013 second_quarter PHA S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. HOUSE OF REPRESENTATIVES,SENATE     0 0 2013-07-15T16:48:23.153000-04:00
1407460 ROCK & ASSOCIATES 498fa068-3053-4d32-ac5b-da816d24776b Q2 ROCK & ASSOCIATES 33545 DIAMONDBACK DRUGS 2013 second_quarter PHA S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. HOUSE OF REPRESENTATIVES,SENATE 6750   0 0 2013-07-15T16:57:42.273000-04:00
1407502 ROCK & ASSOCIATES 1d8d2c2f-fa5e-420d-a3b4-822ebda287c5 Q2 ROCK & ASSOCIATES 33545 VETERINARY PHARMACIES OF AMERICA, INC. 2013 second_quarter PHA S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. HOUSE OF REPRESENTATIVES,SENATE 9375   0 0 2013-07-15T17:12:02.090000-04:00
1407531 ALZHEIMER'S FOUNDATION OF AMERICA ddca328a-ddb0-4476-8a43-ba64558dced6 Q2 ALZHEIMER'S FOUNDATION OF AMERICA 323158 ALZHEIMER'S FOUNDATION OF AMERICA 2013 second_quarter PHA CMS national coverage decision on PET imaging for AD diagnosis. Administration on Aging,Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office   26250 0 0 2013-07-15T17:21:14.817000-04:00
1407540 ROCK & ASSOCIATES b9b6673c-dc36-40e8-8941-fe4e67c331d7 Q2 ROCK & ASSOCIATES 33545 WEDGEWOOD VILLAGE PHARMACY, INC. 2013 second_quarter PHA S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. HOUSE OF REPRESENTATIVES,SENATE 9375   0 0 2013-07-15T17:26:18.517000-04:00
1407548 ALZHEIMER'S FOUNDATION OF AMERICA 85824621-1614-45ae-a2fb-8929456a67ec Q2 ALZHEIMER'S FOUNDATION OF AMERICA 323158 ALZHEIMER'S FOUNDATION OF AMERICA 2013 second_quarter PHA CMS national coverage decision on PET imaging for AD diagnosis. Administration on Aging,Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office   26250 0 0 2013-07-15T17:29:22.497000-04:00
1407614 THE OUTLAW GROUP 6768ad69-3655-4900-be24-afbaa80691bb Q2 THE OUTLAW GROUP 46095 SENTRY DATA SYSTEMS 2013 second_quarter PHA Congressional interest and efforts impacting the 340B prescription drug program. HOUSE OF REPRESENTATIVES     0 0 2013-07-15T19:27:01.607000-04:00
1407674 GREATER NEW YORK HOSPITAL ASSOCIATION 013896f5-017b-43ef-ae2e-d8f020ec4e0b Q2 GREATER NEW YORK HOSPITAL ASSOCIATION 16830 GREATER NEW YORK HOSPITAL ASSOCIATION 2013 second_quarter PHA Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including drug shortage legislation, implementation of P.L. 112-144, medical device pricing and tax issues (including gag clauses), and preserving access to group purchasing organizations (GPOs); drug compounding bills (S.959 & H.R.2090); 340b HRSA guidance on the GPO exclusion (HRSA Release 2013-1); FDA mobile health guidance (FDA-2011-D-0530); track and trace bills (S.957 &H.R.1919). Centers For Medicare and Medicaid Services (CMS),Federal Emergency Management Agency (FEMA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Internal Revenue Service (IRS),SENATE,White House Office   290000 0 0 2013-07-16T09:30:27.253000-04:00
1408022 WHITMER & WORRALL, LLC 5c74551d-44d9-4b75-952e-e2ea52f736a0 Q2 WHITMER & WORRALL, LLC 292892 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) 2013 second_quarter PHA Issues related to monitoring healthcare reform. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,State, Dept of (DOS) 30000   0 0 2013-07-16T12:07:18.650000-04:00
1408081 PRINTING INDUSTRIES OF AMERICA, INC. 18cfad10-03ee-4e18-a866-5391abf21314 Q2 PRINTING INDUSTRIES OF AMERICA, INC. 32203 PRINTING INDUSTRIES OF AMERICA INC 2013 second_quarter PHA Pharmaceutical labeling Consumer Product Safety Commission (CPSC),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Government Printing Office (GPO),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Postal Rate Commission,Postal Regulatory Commission,SENATE,State, Dept of (DOS),Treasury, Dept of,U.S. Postal Service (USPS)   128129 0 0 2013-07-16T12:31:44.067000-04:00
1408390 HAAKE & ASSOCIATES 43047ef2-9907-4fef-8ca2-7710a4c8abd7 Q2 HAAKE & ASSOCIATES 17226 JOHNSON & JOHNSON SERVICES INC. 2013 second_quarter PHA Policy and procurement matters related to vaccines Air Force, Dept of,Army, Dept of (Other),Defense, Dept of (DOD),Navy, Dept of,U.S. Coast Guard (USCG),U.S. Marines 30000   0 0 2013-07-16T14:42:51.667000-04:00
1408458 AMERICAN VETERINARY MEDICAL ASSOCIATION d82a496e-6d8f-44a4-bfd6-121a07bd16dc Q2 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2013 second_quarter PHA H.R. 1150 Preservation of Antibiotics for Medical Treatment Act; S. 959, Pharmaceutical Quality, Security, and Accountability Act; S. 622, Animal Drug and Animal Generic Drug User Fee Act; H.R.1407, Animal Drug User Fee Act; H.R. 1408 Animal Generic Drug User Fee Act; H.R. 1528/S. 1171 Veterinary Medicine Mobility Act; Fairness to Pet Owners Act/Veterinary Prescription writing. Inquiries to and discussions with Federal Trade Commission on veterinary pet prescriptions.Discussions with DEA regarding regulations impending practice of veterinary medicine; seeking clarification of interpretation of existing statute. Discussions with Congressional staff and FDA expressing the need for compounding of medications for use in animals. Discussions with Congressional staff in opposition to language regarding data collection being attached to the Animal Drug User Fee reauthorization language. S. 950/H.R. 1528, Veterinary Medicine Mobility Act of 2013 Agriculture, Dept of (USDA),Defense, Dept of (DOD),Executive Office of the President (EOP),Federal Trade Commission (FTC),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Office of Management & Budget (OMB),SENATE   190000 0 0 2013-07-16T14:56:22.517000-04:00
1408559 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. ba75dbde-082c-449b-86fb-13f5fec29400 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 AMERICAN SOCIETY OF HEMATOLOGY 2013 second_quarter PHA Issues related to drug shortages. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 30000   0 0 2013-07-16T15:10:14.347000-04:00
1408679 WINSTON & STRAWN LLP d4c550b7-a054-479d-bb68-eb9362e30e0e Q2 WINSTON & STRAWN LLP 41682 FRESENIUS KABI USA (FORMERLY KNOWN AS APP PHARMACEUTICALS INC ) 2013 second_quarter PHA Represent the client on issues related to assuring a safe, reliable supply of heparin and also on patent matters, including settlements and extensions. HOUSE OF REPRESENTATIVES,SENATE     0 0 2013-07-16T15:25:00.310000-04:00
1408823 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 2b2fa3e8-86ab-4923-ad0f-75b776da0284 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 THE HEMOPHILIA ALLIANCE 2013 second_quarter PHA issues related to the 340B drug discount program. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2013-07-16T16:01:04.417000-04:00
1408861 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 847d1c4c-00e3-4677-89aa-e1bbf91400bd Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL HEMOPHILIA FOUNDATION 2013 second_quarter PHA Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program. HR 460 - Patients Access to Treatment Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 50000   0 0 2013-07-16T16:11:21.973000-04:00
1408901 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 0707585d-0848-482f-9e83-ad0fc4286b99 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL ASSOCIATION OF EPILEPSY CENTERS 2013 second_quarter PHA Issues related to anti-epileptic drugs. Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 0 2013-07-16T16:13:30.910000-04:00
1409467 NAHIGIAN STRATEGIES, LLC c14d4a26-1e37-40c3-9edc-dd4883f58e2b Q2 NAHIGIAN STRATEGIES, LLC 322897 TEVA PHARMACEUTICALS USA INC 2013 second_quarter PHA Generic and brand drug patent and antitrust issues. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2013-07-17T10:26:29.850000-04:00
1409887 CAPITOLOGIC LLC afb6d9a3-f543-4259-9a09-dca3fc5508b9 Q2 CAPITOLOGIC LLC 400426045 BULALAW, LLC 2013 second_quarter PHA Federal funding of illegal prescription drug market interventions Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute of Justice,Office of Justice Program,SENATE     0 0 2013-07-17T12:38:23.950000-04:00
1409951 MR. VINCENT A. PANVINI 1aea7349-08d9-4793-9804-3edd03c46919 Q2 MR. VINCENT A. PANVINI 401008845 ELI LILLY AND COMPANY 2013 second_quarter PHA Medicare Pt D, Transpacific Partnership HOUSE OF REPRESENTATIVES     0 0 2013-07-17T13:15:47.153000-04:00
1409961 INDEPENDENT PHARMACY COOPERATIVE a1c7683f-e8c6-4eb8-8427-45c907ca5b6f Q2 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2013 second_quarter PHA Tax Payer Relief Act 2013 Implementation of Diabetic Supply Reimbursement Changes SB 959 Pharmaceutical Compounding Quality and Accountability Act Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE     0 0 2013-07-17T13:22:49.443000-04:00
1409977 MR. VINCENT A. PANVINI 08bdf48d-a9b3-44eb-a78d-0e7666338cb2 Q2 MR. VINCENT A. PANVINI 401008845 PHRMA 2013 second_quarter PHA Medicare Part D, Transpacific Partnership HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2013-07-17T13:30:56.610000-04:00
1410195 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 797f28a0-1deb-487e-b89c-5e37c54ec472 Q2 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 24486 ALLIED MEDICAL SUPPLY, INC. 2013 second_quarter PHA Issues affecting resellers of pharmaceutical products in HR 1919 and S. 957 HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2013-07-17T14:36:25.090000-04:00
1410345 MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY 260cf8b5-ca6e-4fc9-8a03-5c0ba863ea89 Q2 MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY 62277 MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY 2013 second_quarter PHA HR 1919 Safeguarding America's Pharmaceutical Act of 2013 and the Senate "track and trace" legislation HOUSE OF REPRESENTATIVES,SENATE   290000 0 0 2013-07-17T15:02:29.897000-04:00
1410380 SMITH GARSON FKA SMITH DAWSON & ANDREWS 6ce47467-e72f-48f9-a21a-43a834c1cf4c 2A SMITH GARSON FKA SMITH DAWSON & ANDREWS 35707 CURE PHARMACEUTICALS 2013 second_quarter PHA Discussed federal government unpaid invoice from 2011 & 2012. HOUSE OF REPRESENTATIVES,SENATE     0 0 2013-07-17T15:06:42.787000-04:00
1410581 RED+BLUE STRATEGIES 3ffc7bf1-2073-4cea-b058-ef1bba60d40c Q2 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2013 second_quarter PHA H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negative impact peoples access to prescription medications through mail. Issues related to the practice of giving coupons for certain prescription medications.Ongoing discussions in the Congress regarding track and trace policies to increase safety in the nation's prescription drug supply chain. CMS call letter focused on changes in policies regarding mail order and pharmacy networks. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2013-07-17T15:39:10.087000-04:00
1410612 SOCIETY OF CHEMICAL MANUFACTURERS & AFFILIATES f013e909-4d8a-4996-8f5e-c681a4f55fcd Q2 SOCIETY OF CHEMICAL MANUFACTURERS & AFFILIATES 37538 SOCIETY OF CHEMICAL MANUFACTURERS & AFFILIATES 2013 second_quarter PHA Activities related to concerns that the federal sequestration will negatively impact the implementation of the Food and Drug Administration's Generic Drug User Fee Act. Environmental Protection Agency (EPA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,SENATE   41000 0 0 2013-07-17T15:45:24.757000-04:00
1410677 ACADEMY OF MANAGED CARE PHARMACY ac1134f1-abf1-4629-a5dc-f4aac471fe52 Q2 ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2013 second_quarter PHA S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs HR 2186 - requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy. S 957 legislation establishes a uniform national policy for the drug supply chain HR 1919 legislation provides enhanced securityin the drug distribution chain HOUSE OF REPRESENTATIVES,SENATE   200000 0 0 2013-07-17T15:51:41.577000-04:00
1410734 KOUNTOUPES DENHAM CARR & REID, LLC 5447e2e0-edb3-4f85-bc3c-c513570c706f Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2013 second_quarter PHA Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2013-07-17T16:04:08.537000-04:00
1411146 KAISER FOUNDATION HEALTH PLAN INC. 199f75e4-49c2-4de9-89e8-6df2b486653b Q2 KAISER FOUNDATION HEALTH PLAN INC. 21027 KAISER FOUNDATION HEALTH PLAN INC 2013 second_quarter PHA S3187 - Food and Drug Administration Safety and Innovation Act: A bill to amend the Federal Food, Drug and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars, and for other purposes. Sponsor: Harkin (IA) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   120000 0 0 2013-07-17T18:04:52.080000-04:00
1411242 UNIVERSITY OF CONNECTICUT edebe444-d005-482c-852b-99122f7656b1 Q2 UNIVERSITY OF CONNECTICUT 39382 UNIVERSITY OF CONNECTICUT 2013 second_quarter PHA S.1244/H.R.2410, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2014, Monitor FDA salaries and expense issues; and extramural research. Education, Dept of,HOUSE OF REPRESENTATIVES,SENATE   60000 0 0 2013-07-17T18:58:16.773000-04:00
1411787 THE OB-C GROUP, LLC 0bec6cd1-b99c-499d-be71-289983ca9f8c Q2 THE OB-C GROUP, LLC 29802 ELI LILLY 2013 second_quarter PHA No specific bill number: matters relating to pharmaceutical manufacturers including Medicare Part D. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2013-07-18T09:59:12.700000-04:00
1411872 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 499f0f3a-f2fd-4d25-99d4-6f7d12310e1a Q2 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2013 second_quarter PHA Rx Pedigree (S. 959, S. 957, H.R. 1919, H.R. 2186); Prescription Drug Monitoring Programs; Drug Abuse (S. 348); Hydrocodone Rescheduling (H.R. 1285, S. 621); Dextromethorphan (S. 644); Prescription Drug Abuse (S. 1277); Drug Shortages - Gray Market (H.R. 1958); Counterfeit Drugs; Importation of Prescription Drugs Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   358000 0 0 2013-07-18T10:12:38.330000-04:00
1411909 BROWN RUDNICK LLP 2aa864bb-302a-4846-bd93-e2d5412a68bb Q2 BROWN RUDNICK LLP 287895 HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC 2013 second_quarter PHA S. 621 & H.R. 1285 - Safe Prescribing Act of 2013; H.R. 1919 - Safeguarding America's Pharmaceuticals Act of 2013; S. 957 & S. 959 - The Drug Supply Chain Security Act; S. 1277- Combating Prescription Drug Abuse Act HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2013-07-18T10:24:51.007000-04:00
1412016 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 6f5da635-888a-4966-80b9-238f5016ca56 Q2 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 31348 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 2013 second_quarter PHA Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio).Regulatory and proposed legislative changes to Medicare part D including pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Regulatory Implementation of the HITECH Act. FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs, 340B program. Issues related to the compounding of certain drugs. S. 77, Prescription Drug and Health Improvement Act S. 557, Medication Therapy Management Empowerment Act H.R. 460, Patients Access to Treatments Act H.R. 1188, Preserving Our Hometown Independent Pharmacies Act H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1024, Medication Therapy Management Empowerment Act S.867, Medicare Prescription Drug Program Integrity and Transparency Act Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE   559764 0 0 2013-07-18T10:46:31.207000-04:00
1412354 DELAHUNT GROUP, LLC 57b68015-51bb-4fcd-99f3-b96d27e05fd9 Q2 DELAHUNT GROUP, LLC 401066001 HEALIANCE PHARMACEUTICALS 2013 second_quarter PHA innovative diabetes treatment HOUSE OF REPRESENTATIVES,Natl Security Agency (NSA),SENATE,State, Dept of (DOS),Treasury, Dept of 45000   0 0 2013-07-18T11:47:03.033000-04:00
1412557 BROWN RUDNICK LLP 23dc5730-4ad0-4d9e-a20f-f4479501add5 2A BROWN RUDNICK LLP 287895 HOSPIRA, INC. 2013 second_quarter PHA H.R. 486- relating to the compounding of drug products House Discussion Draft amending 503A of FFDCA with respect to pharmacy compounding HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2013-07-18T12:11:23.250000-04:00
1412597 ENDO INTERNATIONAL 9306a16e-7129-4809-9f90-f455b17bc76d Q2 ENDO INTERNATIONAL 40011075 ENDO INTERNATIONAL 2013 second_quarter PHA Issues related to tamper resistant formulation of pharmaceutical drugs Life Sciences Jobs and Investment Act HOUSE OF REPRESENTATIVES,SENATE   450000 0 0 2013-07-18T12:16:36.027000-04:00
1412666 RUBICON ADVISORS, LLC fa95d955-0e43-498b-96d1-ef3421ffa928 Q2 RUBICON ADVISORS, LLC 315091 TEVA PHARMACEUTICALS USA 2013 second_quarter PHA Patent Settlements H.R. 1432, Generic Biologies S H.R. 1695, H.R. 5629, Physican Payment Sunshine Act S 2029, Patent Reform H.R. 1908, Import Safety Act H.R. 3100 Affodable Health Choices Act HOUSE OF REPRESENTATIVES,SENATE 105000   0 0 2013-07-18T12:32:01.297000-04:00
1412682 RUBICON ADVISORS, LLC ec549a9b-be7c-487d-b53b-4102598da033 Q2 RUBICON ADVISORS, LLC 315091 WATSON PHARMACEUTICALS INC 2013 second_quarter PHA Patent Reform H.R. 1908, Import Safety Act H.R. 2100 Affordable Health Choices Act Patent Settlements H.R. 1432 S 316 Generic Biologics S 1685 H.R. 5629 Physician Payment Sunshine Act S 2029 HOUSE OF REPRESENTATIVES,SENATE 98000   0 0 2013-07-18T12:37:09.150000-04:00
1412683 RUBICON ADVISORS, LLC 38c3715b-7979-400f-8711-e2fa1570511a Q2 RUBICON ADVISORS, LLC 315091 STATE MUTUAL INSURANCE COMPANY 2013 second_quarter PHA Pharmacy - Compounding HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2013-07-18T12:38:09.777000-04:00
1412711 RUBICON ADVISORS, LLC 1af79f94-2749-4ea6-b514-fe2985284ec1 Q2 RUBICON ADVISORS, LLC 315091 BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2013 second_quarter PHA Physician Payment Sunshine Act S 2029 Patent Settlements H.R. 14328 .316 Affordable Healthcare Choices Act HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2013-07-18T12:45:19.567000-04:00
1412787 ALCALDE & FAY a9c1b9eb-db41-47e9-b5af-c9213244b693 Q2 ALCALDE & FAY 818 CITY OF KENMORE, WASHINGTON 2013 second_quarter PHA DEA regulations on disposal of controlled substances; Marijuana Legalization issues; White House Office of National Drug Control Policy Army, Dept of (Corps of Engineers),Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT),White House Office 20000   0 0 2013-07-18T13:01:50.810000-04:00
1412847 THORN RUN PARTNERS 966b026b-8c1b-4871-ab57-2ba23df964e5 2T THORN RUN PARTNERS 400534596 LONG TERM CARE PHARMACY ALLIANCE 2013 second_quarter PHA Issues related to short-cycle dispensing. Issues related to PBM audit legislation. HOUSE OF REPRESENTATIVES,SENATE 30000   0 1 2013-07-18T13:15:13.250000-04:00
1412855 MEHLMAN CONSULTING, INC. 43410dbe-140b-46f4-bbe5-51fd2b2e1381 Q2 MEHLMAN CONSULTING, INC. 284950 PROCTER & GAMBLE 2013 second_quarter PHA Preventing Abuse of Cough Treatments Act of 2013 (S. 644) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2013-07-18T13:16:16.563000-04:00
1412866 KNIGHT CAPITOL CONSULTANTS b5afc4e5-1fab-4fe9-9733-9f258baa528f Q2 KNIGHT CAPITOL CONSULTANTS 40036301 GENZYME CORPORATION 2013 second_quarter PHA Adequate funding for programs of the Food and Drug Administration, including implementation of the Prescription Drug User Fee Act (FY 2014 appropriations for the FDA, H.R. 2410/S. 1244). Assess potential impact of sequestration on public health/food and drug programs (FY 2014 appropriations for HHS, S. 1284). HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2013-07-18T13:19:22.280000-04:00
1412870 HOSPIRA, INC. 4de1cb7a-248f-467a-8144-20469bf77001 Q2 HOSPIRA, INC. 318711 HOSPIRA INC 2013 second_quarter PHA H.R. 486 - relating to the compounding of drug products House Discussion Draft amending 503A of FFDCA with respect to pharmacy compounding S. 959 Compounding and Pedigree bill HOUSE OF REPRESENTATIVES,SENATE   240000 0 0 2013-07-18T13:19:23.217000-04:00
1412914 ELI LILLY AND COMPANY b9e02363-d45d-489a-824c-41f27c0ac84f Q2 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2013 second_quarter PHA Hospital discounts (HR 3590) Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   1965000 0 0 2013-07-18T13:24:37.947000-04:00
1413039 RED+BLUE STRATEGIES d17ef4c1-f56f-4466-a326-779369b71083 Q2 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2013 second_quarter PHA Issues related to continuing to increase the supply of new and innovative antibiotics that will help to treat the myriad antibiotic resistant strains of bugs like MRSA.H.R. 933 - Consolidation and Further Continuing Appropriations Act of 2013 - Focused on funding for the FDA, CDC and other public health related industries. H.R. 2186 - VALID Compounding Act - Focused on increasing safety for compounded drugs S. 959 - Pharmaceutical Compounding Quality and Accountability Act - Focused on compounding and continued work on issues related to downstream supply chain safety of prescription medications Continued work on issues related to downstream supply chain safety of prescription medications Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2013-07-18T14:02:41.137000-04:00
1413307 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION f306b6d0-e7e2-493a-9ebd-276ade892b37 Q2 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2013 second_quarter PHA H.R. 2375- Transparency and Accountability in Medicare Bidding Act of 2013; Fairness for Small Pharmacies in Preferred Networks; Repeal of National Mail Order Program for Diabetes Testing Supplies Home Delivery; S.644- The Preventing Abuse of Cough Treatments Act of 2013; H.R. 1285- To Amend the Controlled Substance Act to Make Any Substance Containing Hydrocodone a Schedule II Drug; S.867- The Medicare Prescription Drug Program Integrity and Transparency Act of 2013;S.621- The Safe Prescribing Act of 2013; H.R. 1024- The Medication Therapy Management Empowerment Act of 2013; H.R. 1188- The Preserving Our Hometown Independent Pharmacies Act of 2013; S. 959, Pharmaceutical Compounding Quality and Accountability Act; S. 957- Drug Supply Chain Security Act; H.R.1919- Safeguarding America's Pharmaceuticals Act of 2013; Discussion House Draft Legislation on Compounded Drugs, Prescription Drug Diversion and Abuse; TRICARE Pharmacy Benefit/Provisions; Medicaid Reimbursment Cuts Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE   210000 0 0 2013-07-18T14:42:26.353000-04:00
1413374 CAPITOL HILL CONSULTING GROUP 2b6f26d4-a467-4cce-b1ca-56fb49310645 Q2 CAPITOL HILL CONSULTING GROUP 72053 ROCK & ASSOCIATES 2013 second_quarter PHA Compounding pharmacy and FDA issues HOUSE OF REPRESENTATIVES,SENATE     0 0 2013-07-18T14:50:55.707000-04:00
1413533 CAPITOL HILL CONSULTING GROUP b0584572-9f43-4388-8cee-8abbad00fc41 Q2 CAPITOL HILL CONSULTING GROUP 72053 WELLNESS PHARMACY 2013 second_quarter PHA Compounding pharmacy and FDA issues; S959, Pharmaceutical Compounding Quality & Accountability Act HOUSE OF REPRESENTATIVES,SENATE 8000   0 0 2013-07-18T15:05:59.963000-04:00
1413560 PRIME POLICY GROUP c99e0cb8-633b-45c1-9e0d-3916973e4d59 Q2 PRIME POLICY GROUP 400532589 GLAXOSMITHKLINE 2013 second_quarter PHA Hearing in Energy and Commerce Committee. Drug supply chain. HOUSE OF REPRESENTATIVES 40000   0 0 2013-07-18T15:10:15.237000-04:00
1413756 HANCE SCARBOROUGH eec6e444-d4de-46fe-9e0e-e08f7ee9e276 Q2 HANCE SCARBOROUGH 17443 ALLIANCE OF INDEPENDENT PHARMACISTS - TEXAS 2013 second_quarter PHA Federal legislation affecting the practice of pharmacy and FDA regulation of compounded drugs. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2013-07-18T15:29:39.770000-04:00
1414060 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING e7ef17e8-15fb-4ef7-85e0-a76036d3e115 Q2 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 35968 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 2013 second_quarter PHA Pharmacy compounding of radiopharmaceuticals; S. 959, Pharmaceutical Quality, Security, and Accountability Act), nuclear medicine provisions. Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Nuclear Regulatory Commission (NRC),SENATE   110000 0 0 2013-07-18T16:06:01.447000-04:00
1414155 HANCE SCARBOROUGH c346d9d5-4dd7-49be-bb60-9cd0f3cd8af0 Q2 HANCE SCARBOROUGH 17443 INTRATHECAL CUSTODY ACCOUNT SUPPORTERS (INFORMAL COALITION) 2013 second_quarter PHA Monitored legislation related to physician control and patient access to intrathecal pump applications for patients with chronic pain. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2013-07-18T16:17:41.497000-04:00
1414162 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 5ec31bf3-96ac-4cc5-9e74-15e2569f14c9 Q2 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 4653 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 2013 second_quarter PHA Proposals relating to the regulation of direct to consumer prescription drug advertising Commerce, Dept of (DOC),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,Natl Telecommunications & Information Administration (NTIA),SENATE   470000 0 0 2013-07-18T16:18:44.357000-04:00
1414893 ARENTFOX SCHIFF LLP 5355ee21-2ad5-40e6-8146-50862a17b1b4 Q2 ARENTFOX SCHIFF LLP 4208 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 2013 second_quarter PHA Pharmacy compounding of medications S. 959 (Pharmaceutical Quality, Security, and Accountability Act), entire bill HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2013-07-18T18:07:54.410000-04:00
1415053 EMPIRE CONSULTING GROUP 77ebc2d1-8547-48a6-a40b-8893694e722b Q2 EMPIRE CONSULTING GROUP 400703105 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2013 second_quarter PHA Issues relating to the Medicare Prescription Drug Act; issues relating to the Affordable Care Act; issues relating to the Independent Payment Advisory Board; H.R. 1588, "Medicare Drug Savings Act of 2013"; H.R. 1919, "Safeguarding America's Pharmaceutical Act of 2013"; and intellectual property issues. HOUSE OF REPRESENTATIVES 30000   0 0 2013-07-18T18:31:44.610000-04:00
1415257 THE INGRAM GROUP LLC 77839028-8363-432b-bac1-06afdb25e281 Q2 THE INGRAM GROUP LLC 400577737 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) 2013 second_quarter PHA Issues related to pharmaceutical importation, issues related to generic drugs, and S.CON.RES.8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023. Issues related to the Drug Supply Chain Security Act of 2013 S.957. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2013-07-18T22:17:58.340000-04:00
1416109 NOVO NORDISK INC. 6758fde1-a069-4a3e-b80b-81e329433ae6 Q2 NOVO NORDISK INC. 284790 NOVO NORDISK INC. 2013 second_quarter PHA H.R.1919 Safeguarding America's Pharmaceuticals Act of 2013 and S.959 Pharmaceutical Compounding Quality and Accountability Act (for track and trace supply chain provisions); issues regarding biosimilars; 340B Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Veterans Affairs, Dept of (VA)   640000 0 0 2013-07-19T10:22:44.750000-04:00
1416223 COVIDIEN LP 2d45c420-5f89-4213-9818-f9d1a1eef06c Q2 COVIDIEN LP 319778 COVIDIEN LP 2013 second_quarter PHA Issues involving controlled substances and pain and addiction drugs generally. Energy, Dept of,Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE,State, Dept of (DOS)   760000 0 0 2013-07-19T10:38:34.847000-04:00
1416612 RASKY PARTNERS, INC. 84943093-4f61-46b4-b7de-1729a95b1fd7 2T RASKY PARTNERS, INC. 297410 ELI LILLY AND CO 2013 second_quarter PHA Monitor biologics related issues, Medicare Part D HOUSE OF REPRESENTATIVES,SENATE     0 1 2013-07-19T11:19:05.893000-04:00
1416671 ARKEMA INC. AND ITS AFFILIATES (FKA ARKEMA INC.) da7b14a8-2102-4a50-957d-887990555989 Q2 ARKEMA INC. AND ITS AFFILIATES (FKA ARKEMA INC.) 13370 ARKEMA INC. AND ITS AFFILIATES (FKA ARKEMA INC.) 2013 second_quarter PHA Food and Drug Administration pharmaceuticals issues Agriculture, Dept of (USDA),Defense, Dept of (DOD),Energy, Dept of,Environmental Protection Agency (EPA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Office of Science & Technology Policy (OSTP),SENATE,State, Dept of (DOS),Surface Transportation Board (STB),Transportation, Dept of (DOT),U.S. Trade Representative (USTR)   140000 0 0 2013-07-19T11:26:33.933000-04:00
1416952 AMERICAN ASSOCIATION OF NURSE PRACTITIONERS 299bca32-25b2-4326-9f42-e9277ef126ed Q2 AMERICAN ASSOCIATION OF NURSE PRACTITIONERS 401040928 AMERICAN ASSOCIATION OF NURSE PRACTITIONERS 2013 second_quarter PHA Legislation and policies relating to: FDA Drug Safety and Risk Management Advisory Committee January 25 recommendation to reschedule hydrocodone as a Schedule II controlled substance H.R. 1285 - To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drugS. 621 Safe Prescribing Act H.R. 1919 - Safeguarding America's Pharmaceuticals Act H.R. 2186 VALID Compounding Act S. 959 Pharmaceutical Compounding Quality and Accountability Act Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE,White House Office   84089 0 0 2013-07-19T11:44:20.793000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 1889.354ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API